Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 21, 2004. The report serves as a notification of changes in directors' interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to reporting specific equity transactions and does not contain financial performance data.
Material Changes
The primary material change reported is a transfer of shares from the GlaxoSmithKline Employee Trust ("GSK Trust") to participants in the SmithKline Beecham Employee Share Option Plan 1991.
- Date of Transaction: January 20, 2004
- Shares Transferred: 15,168 Ordinary Shares
- Trustee: Abacus (GSK) Trustees Limited
Management Commentary and Risks
The filing notes that the GSK Trust is a discretionary trust where all current and former employees are potential beneficiaries. Consequently, three directors—Dr. J-P Garnier, Dr. T Yamada, and Mr. J D Coombe—are interested in the shares held in the trust in the same manner as other employees. No specific risks, contingencies, or unusual items regarding operations were disclosed in this text.
Investor Verification Points
- Verify the total number of shares held by the GSK Trust prior to and after the January 20, 2004 transfer.
- Confirm the specific allocation of the 15,168 shares among the individual participants of the 1991 Share Option Plan.
- Review the full 20-F annual report for comprehensive financial performance data, as this 6-K filing does not contain such metrics.